“Today’s announcement gives patients and their families hope.”
A critical drug thought to help stop Alzheimer’s has returned positive results in a new study, providing hope for those diagnosed with the disease. Eisai and Biogen said Tuesday that their drug, lecanemab, slowed the decline for those diagnosed with early indications of the disease after it reduced the build-up of amyloid beta in the brains of those in the study.
” The drug reduced cognitive decline by 27 percent in people who received the drug compared to a placebo, the study reported. “Today’s announcement gives patients and their families hope that lecanemab, if approved, can potentially slow the progression of Alzheimer’s disease, and provide a clinically meaningful impact on cognition and function,” said Michel Vounatsos, chief executive officer at Biogen.